EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 156 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $577,245 | -68.2% | 36,604 | -46.7% | 0.00% | -75.0% |
| Q3 2022 | $1,815,000 | -62.2% | 68,686 | -36.4% | 0.01% | -60.0% |
| Q2 2022 | $4,796,000 | -30.4% | 107,947 | -22.5% | 0.02% | -16.7% |
| Q1 2022 | $6,893,000 | -7.6% | 139,273 | -4.9% | 0.02% | 0.0% |
| Q4 2021 | $7,458,000 | -0.1% | 146,473 | +9.5% | 0.02% | -7.7% |
| Q3 2021 | $7,462,000 | +26.5% | 133,773 | -3.0% | 0.03% | +23.8% |
| Q2 2021 | $5,901,000 | -0.9% | 137,873 | -3.4% | 0.02% | -19.2% |
| Q1 2021 | $5,955,000 | +25.2% | 142,673 | +39.7% | 0.03% | +23.8% |
| Q4 2020 | $4,756,000 | -9.7% | 102,120 | -17.6% | 0.02% | 0.0% |
| Q3 2020 | $5,264,000 | +63.5% | 123,920 | +84.7% | 0.02% | +31.2% |
| Q2 2020 | $3,219,000 | +1.9% | 67,087 | -2.3% | 0.02% | -20.0% |
| Q1 2020 | $3,160,000 | -38.3% | 68,692 | -19.4% | 0.02% | +17.6% |
| Q4 2019 | $5,122,000 | -15.1% | 85,258 | -20.0% | 0.02% | -22.7% |
| Q3 2019 | $6,032,000 | -20.5% | 106,622 | -21.7% | 0.02% | -18.5% |
| Q2 2019 | $7,586,000 | +875.1% | 136,235 | +784.6% | 0.03% | +800.0% |
| Q1 2019 | $778,000 | +135.0% | 15,400 | +222.9% | 0.00% | +200.0% |
| Q3 2018 | $331,000 | – | 4,769 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |